21:14 , Oct 13, 2017 |  BC Week In Review  |  Financial News

Catalent proposes $450M notes offering

On Oct. 10, drug delivery and development solutions company Catalent Inc. (NYSE:CTLT) said its Catalent Pharma Solutions Inc. subsidiary proposed to raise $450 million through the sale of senior unsecured notes due in 2026. Catalent...
23:49 , Mar 6, 2017 |  BC Week In Review  |  Clinical News

VAL-1221: Ph I/II started

Next month, Valerion will begin an open-label, international Phase I/II trial to evaluate 1, 3 and 10 mg IV VAL-1221 every 2 weeks for 12 weeks in up to 16 ambulatory and ventilator-free patients with...
08:00 , Jan 26, 2015 |  BC Week In Review  |  Company News

Sellas, Catalent Pharma deal

Catalent and Sellas partnered to reprofile insomnia drug zolpidem to treat Parkinson’s disease (PD) and progressive supranuclear palsy (PSP) using Catalent’s OSDrC OptiDose drug delivery technology. Catalent will develop the formulation and manufacture and distribute...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Company News

Valerion, Catalent deal

Catalent's Catalent Pharma Solutions Inc. subsidiary and Valerion partnered to develop Valerion's two lead preclinical candidates, VAL-1205 and VAL-1221 . VAL-1205 is the delivery antibody 3E10 which the company plans on conjugating with active moieties...
07:00 , May 26, 2014 |  BioCentury  |  Finance

Europe's Iceberg 2014: Premier League teams

Competing in biotech's Premier League requires deep pockets, long term planning and the risk appetite to pursue novel technologies or targets that don't always pan out. BioCentury's 12th annual European Iceberg survey reveals that for...
07:00 , Oct 10, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Hypercholesterolemia; hyperlipidemia ATP-binding cassette sub-family A member 1 (ABCA1); microsomal triglyceride transfer protein (MTTP; MTP) Mouse studies suggest inhibiting MTP and ABCA1 in the...
07:00 , May 27, 2013 |  BioCentury  |  Finance

Value reality check

Europe's economic crisis has created a new reality. Austerity measures at the national level have placed an even higher premium than in the past on controlling healthcare costs, resulting in an increasingly tough reimbursement environment...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Catalent Pharma, Redwood Bioscience deal

Redwood granted Catalent exclusive rights to market antibody-drug conjugate (ADC) therapies using Redwood's SMARTag technology. Catalent took an undisclosed minority stake in Redwood, which may increase over time up to a potential acquisition. Catalent said...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

Aegerion sales and marketing update

Aegerion provided pricing for its homozygous familial hypercholesterolemia (hoFH) drug Juxtapid lomitapide in a presentation at the 31st annual JPMorgan Healthcare Conference on Jan. 8. The company said the U.S. annual gross price per patient...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Company News

Catalent Pharma, UMN Pharma deal

Catalent granted UMN rights to use Catalent's GPEx gene product expression technology to produce cell lines for the development of biosimilars. Under the deal, UMN and its Unigen contract manufacturing subsidiary will produce "a number...